🔎 Trials Near Me

Utama › Kanser Prostat › Nebraska

Kajian klinikal Kanser Prostat di Nebraska

27 kajian untuk Kanser Prostat sedang mencari peserta di lokasi di Nebraska.

Bandar di Nebraska

Teks kajian rasmi (Bahasa Inggeris)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • CHI Health Saint Francis, Grand Island
  • CHI Health Good Samaritan, Kearney
  • Alegent Health Immanuel Medical Center, Omaha
  • dan 2 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 40 hingga 75 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT05334069

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors

  • Nebraska Medicine-Bellevue, Bellevue
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 2
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT03866382

Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer

  • Urology Cancer Center, PC, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Lelaki · Dikemas kini 25 Sep 2026 · NCT06800313

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

  • Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0026), Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT06136650

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

  • Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 2/3
Umur 18 hingga 100 · Lelaki · Dikemas kini 22 Sep 2026 · NCT06780670

Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC

  • Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 3
Umur 18 hingga 100 · Lelaki · Dikemas kini 22 Sep 2026 · NCT06855277

PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer

  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 2
Umur 30 ke atas · Lelaki · Dikemas kini 21 Sep 2026 · NCT07234981

A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer

  • XCancer, Omaha
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 15 Sep 2026 · NCT07581184

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

  • XCancer Omaha LLC, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 11 Sep 2026 · NCT06056830

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

  • Nebraska Medicine-Bellevue, Bellevue
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 10 Sep 2026 · NCT05946213

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

  • Research Site, Omaha
Mengambil pesertaFasa 1/2
Umur 18 hingga 99 · Lelaki · Dikemas kini 27 Ogo 2026 · NCT07590934

AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)

  • Research Site, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 26 Ogo 2026 · NCT07611110

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

  • XCancer Omaha, Omaha
Mengambil pesertaFasa 2
Umur 18 ke atas · Lelaki · Dikemas kini 24 Ogo 2026 · NCT07745361

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

  • Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Lelaki · Dikemas kini 20 Ogo 2026 · NCT06785636

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

  • CHI Health Good Samaritan, Kearney
  • Alegent Health Bergan Mercy Medical Center, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 19 Ogo 2026 · NCT04423211

Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer

  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 2
Umur 30 ke atas · Lelaki · Dikemas kini 19 Ogo 2026 · NCT07237269

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

  • CHI Health Saint Francis, Grand Island
  • CHI Health Good Samaritan, Kearney
  • Alegent Health Immanuel Medical Center, Omaha
  • dan 2 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 14 Jul 2026 · NCT06592924

Integrated Cancer Repository for Cancer Research

  • Mary Lanning Healthcare, Morrison Cancer Center, Hastings
  • Faith Regional Health Services, Carson Cancer Center, Norfolk
  • Great Plains Regional Medical Center, North Platte
  • dan 3 lagi
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
Umur 19 hingga 110 · Semua jantina · Dikemas kini 29 Jun 2026 · NCT02012699

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

  • Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
  • XCancer Omaha / Urology Cancer Center, Omaha
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 11 Jun 2026 · NCT05283330

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

  • Urology Cancer Center PC, Omaha
  • Nebraska Cancer Specialists, Omaha
Mengambil pesertaFasa 4
Umur 18 hingga 100 · Lelaki · Dikemas kini 4 Jun 2026 · NCT05803941

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

  • XCancer Omaha / Urology Cancer Center, Omaha
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Lelaki · Dikemas kini 14 Mei 2026 · NCT05413850

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Research Site, Omaha
Mengambil pesertaFasa 1
Umur 18 ke atas · Lelaki · Dikemas kini 12 Mei 2026 · NCT06879041

Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

  • CHI Health Good Samaritan, Kearney
  • Saint Elizabeth Regional Medical Center, Lincoln
  • Alegent Health Immanuel Medical Center, Omaha
  • dan 4 lagi
Mengambil pesertaFasa 2
Umur 18 ke atas · Lelaki · Dikemas kini 29 Jan 2026 · NCT05806515

Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

  • Nebraska Medicine-Bellevue, Bellevue
  • Nebraska Medicine-Village Pointe, Omaha
  • University of Nebraska Medical Center, Omaha
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 22 Jan 2026 · NCT06470243

High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer

  • University of Nebraska Medical Center, Omaha
Mengambil peserta
Umur 19 ke atas · Lelaki · Dikemas kini 5 Nov 2025 · NCT05754580

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Omaha
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 28 Okt 2025 · NCT03452774

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

  • Nebraska Medicine-Bellevue, Bellevue
  • Nebraska Methodist Hospital, Omaha
  • Nebraska Medicine-Village Pointe, Omaha
  • dan 1 lagi
Mengambil pesertaFasa 3
Umur 18 ke atas · Lelaki · Dikemas kini 11 Sep 2025 · NCT03678025

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.